Multiple Milner affiliates recognised at Cambridge Independent Science and Technology Awards
We are delighted that several of our affiliated companies were recognised at the 2023 Cambridge Independent Science & Technology Awards last night. Among the list of awardees was Cardiatec Biosciences, an AI drug target discovery company co-founded by Milner Head...
Dr Cathy Tralau-Stewart appointed Executive Director of the Milner Therapeutics Institute
We are delighted to welcome Dr Cathy Tralau-Stewart as the new Executive Director at the Milner Therapeutics Institute. Cathy will work alongside Director Tony Kouzarides and the Milner team to lead and deliver our vision to transform pioneering science into...
Milner welcomes new Head of Target Discovery
We are delighted to welcome Dr Erica Bello as the new Head of Target Discovery at the Milner Therapeutics Institute. Erica brings to the team broad experience in CRISPR screening and advanced disease models, both from her work at the Wellcome Sanger Institute and more...
Milner Institute collaborates to launch Cambridge AI Club for Biomedicine
The AI Club for Biomedicine, launched earlier this month, is a new initiative created to bring together the biomedical AI and machine learning community in Cambridge. This collaboration between the Milner and CRUK Cambridge Institute will be held on the first Thursday...
Milner Institute announces strategic collaboration with NC3Rs
We are delighted to announce a new collaboration with the NC3Rs this month, which has been established to help NC3Rs-funded researchers translate their in vitro models of human disease into industry-relevant genetic assays. The collaboration involves a funding...
Milner affiliate STORM Therapeutics initiate phase I clinical trials
Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class compound against the RNA modifying enzyme, METTL3. STORM Therapeutics is a clinical stage biotechnology company creating...
MSD joins Milner Therapeutics Consortium
This month we are excited to announce that MSD has joined the Milner Therapeutics Consortium as our 12th pharma partner. This coincides with the company’s investment in a new Discovery Centre in London, located in the heart of the Knowledge Quarter. MSD scientists in...
Milner pharma partner visit to Barcelona affiliated institutes
A long-term priority for the Milner is to share our experience of working with industry with other academic institutes, with the goal of fostering wider cross-sector collaboration. Colleagues from affiliated academic institutes have participated in our annual...